Dry Eye Disease Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Quorum Innovations, Serentrix, IVIEW Therapeutics, Taejoon Pharmaceutical, Seinda Pharmaceutical

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dry Eye Disease pipeline constitutes 45+ key companies continuously working towards developing 50+ Dry Eye Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Dry Eye Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dry Eye Disease Market.

The Dry Eye Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Dry Eye Disease Pipeline Report: https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Dry Eye Disease treatment therapies with a considerable amount of success over the years.
• Dry Eye Disease companies working in the treatment market are Quorum Innovations, Serentrix, IVIEW Therapeutics, Taejoon Pharmaceutical, Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc., Aramis Biosciences, Kowa Company, Alcon, HanAll Biopharma, Seikagaku Corporation, Novaliq GmbH, and others, are developing therapies for the Dry Eye Disease treatment
• Emerging Dry Eye Disease therapies in the different phases of clinical trials are- Qi 401, SER-114, iVIEW 1001, TJO-083, SY-201, INV-102, GLH8NDE, SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol, and others are expected to have a significant impact on the Dry Eye Disease market in the coming years.
• In February 2023, Novaliq announced its plans for filing a Marketing Authorization Application (MAA) for CyclASol(ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED)in the European Union.
• In November 2022, Aerie Pharmaceuticals initiated a 12-month, multicenter, vehiclecontrolled, double-masked, randomized Phase 3 study conducted at approximately 10 sites in the United States. Allsubjects enrolled will have dry eye disease (DED).
• In April 2022, Novaliq announced that data from the second pivotal Phase 3 trial (ESSENCE-2) evaluating theinvestigational drug CyclASol® for the treatment of dry eye disease (DED), was presented as part of a podium symposium atthe American Cataract and Refractive Surgery (ASCRS) annual meeting in Washington D.C. on April 24, 2022.

Dry Eye Disease Overview
The multifactorial condition of the ocular surface known as dry eye disease (DED), also known as dry eye syndrome (DES), keratoconjunctivitis sicca (KCS), and keratitis sicca, is brought on by a loss of the tear film's homeostasis. Due to underlying tear film instability, ocular suface inflammation and injury, and neuorsensory anomalies, it frequently causes ocular discomfort and visual disruption.

Get a Free Sample PDF Report to know more about Dry Eye Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Dry Eye Disease Drugs Under Different Phases of Clinical Development Include:
• Qi 401: Quorum Innovations
• SER-114: Serentrix
• iVIEW 1001: IVIEW Therapeutics
• TJO-083: Taejoon Pharmaceutical
• SY-201: Seinda Pharmaceutical
• INV-102: Invirsa
• GLH8NDE: GL Pharm Tech Corporation
• SHJ 002: Dreamhawk Vision Biotech, Inc.
• A197: Aramis Biosciences
• K-161: Kowa Company
• AR-15512: Alcon
• HL036: HanAll Biopharma
• SI-614: Seikagaku Corporation
• NOV03: Novaliq GmbH
• CyclASol: Novaliq GmbH
• HL036: HanAll Biopharma
• OTX-DED: Ocular Therapeutix

Dry Eye Disease Route of Administration
Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Dry Eye Disease Molecule Type
Dry Eye Disease Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Dry Eye Disease Pipeline Therapeutics Assessment
• Dry Eye Disease Assessment by Product Type
• Dry Eye Disease By Stage and Product Type
• Dry Eye Disease Assessment by Route of Administration
• Dry Eye Disease By Stage and Route of Administration
• Dry Eye Disease Assessment by Molecule Type
• Dry Eye Disease by Stage and Molecule Type

DelveInsight's Dry Eye Disease Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Dry Eye Disease product details are provided in the report. Download the Dry Eye Disease pipeline report to learn more about the emerging Dry Eye Disease therapies at:
https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Dry Eye Disease Therapeutics Market include:
Key companies developing therapies for Dry Eye Disease are - AbbVie Inc. (Allergan PLC), AFT Pharmaceuticals, Akorn, Alcon Inc., Bausch Health Companies Inc., Horus Pharma, Johnson & Johnson, Mitotech, Novaliq GmbH, OASIS Medical, Otsuka Pharmaceutical Co. Ltd, Prestige Consumer Healthcare, Santen Pharmaceutical Co. Ltd, Sentiss Pharma Pvt. Ltd, Sun Pharmaceutical Industries Ltd, VISUfarma, and others.

Dry Eye Disease Pipeline Analysis:
The Dry Eye Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dry Eye Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Eye Disease Treatment.
• Dry Eye Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dry Eye Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Eye Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dry Eye Disease drugs and therapies-
https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dry Eye Disease Pipeline Market Drivers
• Rise in geriatric population, increasing Exposure to computer screens, increased R&D Activities, adoption of new Technologies are some of the important factors that are fueling the Dry Eye Disease Market.

Dry Eye Disease Pipeline Market Barriers
• However, lack of awareness about dry eye disease in low income countries, complexity of the disease, challenges associated with the Ocular drug delivery and other factors are creating obstacles in the Dry Eye Disease Market growth.

Scope of Dry Eye Disease Pipeline Drug Insight
• Coverage: Global
• Key Dry Eye Disease Companies: Quorum Innovations, Serentrix, IVIEW Therapeutics, Taejoon Pharmaceutical, Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc., Aramis Biosciences, Kowa Company, Alcon, HanAll Biopharma, Seikagaku Corporation, Novaliq GmbH, and others
• Key Dry Eye Disease Therapies: Qi 401, SER-114, iVIEW 1001, TJO-083, SY-201, INV-102, GLH8NDE, SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol, and others
• Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and Dry Eye Disease emerging therapies
• Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers

Request for Sample PDF Report for Dry Eye Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Dry Eye Disease Report Introduction
2. Dry Eye Disease Executive Summary
3. Dry Eye Disease Overview
4. Dry Eye Disease- Analytical Perspective In-depth Commercial Assessment
5. Dry Eye Disease Pipeline Therapeutics
6. Dry Eye Disease Late Stage Products (Phase II/III)
7. Dry Eye Disease Mid Stage Products (Phase II)
8. Dry Eye Disease Early Stage Products (Phase I)
9. Dry Eye Disease Preclinical Stage Products
10. Dry Eye Disease Therapeutics Assessment
11. Dry Eye Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Dry Eye Disease Key Companies
14. Dry Eye Disease Key Products
15. Dry Eye Disease Unmet Needs
16 . Dry Eye Disease Market Drivers and Barriers
17. Dry Eye Disease Future Perspectives and Conclusion
18. Dry Eye Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Dry Eye Disease Market https://www.delveinsight.com/report-store/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dry Eye Disease-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Dry Eye Disease Epidemiology https://www.delveinsight.com/report-store/dry-eye-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Dry Eye Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.